drugset / Trial / NCT00842140
Safety of Hormonal Contraceptives Therapies in Polycystic Ovary Syndrome (PCOS) Women
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study to assess early markers of cardiovascular disease in women with polycystic ovary syndrome in use of oral contraceptive containing ethynilestradiol and chlormadinone acetate alone or associated with Spironolactone.
Timeline
- Start
- 2006-02
- Primary completion
- 2009-01
- Completion
- 2009-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 850 mg | — |
| Subject | Spironolactone | Small molecule | 100 mg | Oral |
| Background | chlormadinone acetate | Small molecule | 2 mg | Oral |
| Background | ethynylestradiol | Unknown | 0.03 mg | Oral |